These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 30565273)

  • 1. BMA-Mod: A Bayesian model averaging strategy for determining dose-response relationships in the presence of model uncertainty.
    Gould AL
    Biom J; 2019 Sep; 61(5):1141-1159. PubMed ID: 30565273
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bayesian model-averaged benchmark dose analysis via reparameterized quantal-response models.
    Fang Q; Piegorsch WW; Simmons SJ; Li X; Chen C; Wang Y
    Biometrics; 2015 Dec; 71(4):1168-75. PubMed ID: 26102570
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Model Uncertainty and Bayesian Model Averaged Benchmark Dose Estimation for Continuous Data.
    Shao K; Gift JS
    Risk Anal; 2014 Jan; 34(1):101-20. PubMed ID: 23758102
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bayesian dose-response analysis for epidemiological studies with complex uncertainty in dose estimation.
    Kwon D; Hoffman FO; Moroz BE; Simon SL
    Stat Med; 2016 Feb; 35(3):399-423. PubMed ID: 26365692
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A flexible Bayesian approach for modeling monotonic dose-response relationships in drug development trials.
    Ohlssen D; Racine A
    J Biopharm Stat; 2015; 25(1):137-56. PubMed ID: 24836192
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of different approaches for dose response analysis.
    Saha S; Brannath W
    Biom J; 2019 Jan; 61(1):83-100. PubMed ID: 30203492
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Frequentist model averaging for analysis of dose-response in epidemiologic studies with complex exposure uncertainty.
    Kwon D; Simon SL; Hoffman FO; Pfeiffer RM
    PLoS One; 2023; 18(12):e0290498. PubMed ID: 38096309
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bayesian effect estimation accounting for adjustment uncertainty.
    Wang C; Parmigiani G; Dominici F
    Biometrics; 2012 Sep; 68(3):661-71. PubMed ID: 22364439
    [TBL] [Abstract][Full Text] [Related]  

  • 9. On the Quantification of Model Uncertainty: A Bayesian Perspective.
    Kaplan D
    Psychometrika; 2021 Mar; 86(1):215-238. PubMed ID: 33721184
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bayesian penalized log-likelihood ratio approach for dose response clinical trial studies.
    Tang Y; Cai C; Sun L; He J
    J Biopharm Stat; 2017; 27(6):975-989. PubMed ID: 28318420
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bayesian nonparametric estimation of continuous monotone functions with applications to dose-response analysis.
    Bornkamp B; Ickstadt K
    Biometrics; 2009 Mar; 65(1):198-205. PubMed ID: 18510655
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Practical considerations for using functional uniform prior distributions for dose-response estimation in clinical trials.
    Bornkamp B
    Biom J; 2014 Nov; 56(6):947-62. PubMed ID: 24984691
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dose response signal detection under model uncertainty.
    Dette H; Titoff S; Volgushev S; Bretz F
    Biometrics; 2015 Dec; 71(4):996-1008. PubMed ID: 26228796
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Part 2. Development of Enhanced Statistical Methods for Assessing Health Effects Associated with an Unknown Number of Major Sources of Multiple Air Pollutants.
    Park ES; Symanski E; Han D; Spiegelman C
    Res Rep Health Eff Inst; 2015 Jun; (183 Pt 1-2):51-113. PubMed ID: 26333239
    [TBL] [Abstract][Full Text] [Related]  

  • 15. cLRT-Mod: An efficient methodology for pharmacometric model-based analysis of longitudinal phase II dose finding studies under model uncertainty.
    Buatois S; Ueckert S; Frey N; Retout S; Mentré F
    Stat Med; 2021 May; 40(10):2435-2451. PubMed ID: 33650148
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Testing effect of a drug using multiple nested models for the dose-response.
    Baayen C; Hougaard P; Pipper CB
    Biometrics; 2015 Jun; 71(2):417-27. PubMed ID: 25660353
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Potential uncertainty reduction in model-averaged benchmark dose estimates informed by an additional dose study.
    Shao K; Small MJ
    Risk Anal; 2011 Oct; 31(10):1561-75. PubMed ID: 21388425
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inference for the existence of hormetic dose-response relationships in toxicology studies.
    Kim SB; Bartell SM; Gillen DL
    Biostatistics; 2016 Jul; 17(3):523-36. PubMed ID: 26873961
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Bayesian approach to a logistic regression model with incomplete information.
    Choi T; Schervish MJ; Schmitt KA; Small MJ
    Biometrics; 2008 Jun; 64(2):424-30. PubMed ID: 17764482
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A comparison of three methods for integrating historical information for Bayesian model averaged benchmark dose estimation.
    Shao K
    Environ Toxicol Pharmacol; 2012 Sep; 34(2):288-296. PubMed ID: 22647377
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.